Skip to main navigation

Investor Relations

July 23, 2021

Abivax publishes a prospectus in the context of its capital increase and bonds offering

July 23, 2021

Abivax announces the pricing of its oversubscribed capital increase of EUR 60M and convertible bonds of EUR 25M, totaling EUR 85M new financing

July 22, 2021

Abivax announces a capital increase and convertible bonds issue to qualified investors for an aggregate amount of approximately EUR 80M

July 02, 2021

Company statement: Jean-Marc Steens, M.D., decides to end his career at Abivax

June 23, 2021

Abivax reports excellent phase 2a clinical safety and efficacy results with 50mg ABX464 in rheumatoid arthritis